Detecting EGFR T790M Mutations From Circulating Tumor Cells
|ClinicalTrials.gov Identifier: NCT01734915|
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : September 26, 2016
|Condition or disease||Intervention/treatment|
|Non Small Cell Lung Cancer||Device: Circulating tumor cell chip|
In order to participate in this study you need to have a diagnosis of NSCLC that has spread or is unable to be surgically removed. In addition, your cancer must have an EGFR mutation and you must have a scheduled (or recently performed) biopsy to check on the presence of any other mutations related to targeted drug resistance.
After you sign consent to participate in this study we will draw a blood sample (three tubes of blood). This is about 6 teaspoons of blood.
The number of CTCs in your blood will not be reported to you since it is not known if this number has any meaning or if it impacts your medical care in any way. These results will not become part of your medical record. They will be kept in a separate, secure location.
We will collect information from your medical records and store it in a research record that we create about you. The study team will use this information to compare details about your medical history with the results of the experiments done on your blood.
Genetic material (DNA) will be removed from the CTCs found in your blood. This genetic material will be stored at the Massachusetts General Hospital and studied along with samples from other participants on this research study. Your samples will not be labeled with your name or any information that identifies you. Your samples will have a study-specific code number on them. The code linking your name to the sample will be kept in a secure location, available only to the investigators of the study and select study team members.
After the blood draw we will follow your status every 6 months by reviewing your medical records.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Detecting EGFR T790M Mutations From Circulating Tumor Cells|
|Study Start Date :||November 2012|
|Primary Completion Date :||September 2016|
|Study Completion Date :||September 2016|
Subjects with advanced NSCLC, will undergo blood draw
Device: Circulating tumor cell chip
three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
Other Name: Herringbone circulating tumor cell chip, herringbone CTC chip, HBCTC chip
- Number of patients with detectable EGFR mutations in their CTCs [ Time Frame: 2 years ]Calculate the number of patients in the study population with detectable EGFR mutations in the CTCs in order to demonstrate the feasibility of testing for EGFR mutations from captured CTCs
- Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping [ Time Frame: 2 yearss ]Determine the concordance of EGFR genotyping from CTCs compared to tumor tissue
- Number of patients with EGFR gentoype results detectable from plasma cfDNA [ Time Frame: 2 years ]Explore the feasibility of EGFR genotyping from plasma circulating free DNA (cfDNA)
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01734915
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02115|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02215|
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|